Replimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?

Key Points

• Replimune Group shares fell 6.6% in midday trading, with the stock hitting an intraday low of $10.44 before last trading around $10.26 on much lighter-than-normal volume.
• Analyst sentiment remains cautious overall: the stock has a consensus Hold rating and an average price target of $8.12, though JPMorgan recently upgraded it to overweight while other firms cut targets or ratings.
• The company missed earnings expectations in its latest quarterly report, posting a loss of $0.76 per share versus estimates of a $0.66 loss, while insiders and institutions continue to show notable ownership activity.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price traded down 6.6% during mid-day trading on Monday . The stock traded as low as $10.44 and last traded at $10.2610. 245,496 shares traded hands during trading, a decline of 95% from the average daily volume of 4,548,816 shares. The stock had previously closed at $10.99.

Wall Street Analysts Forecast Growth

REPL has been the subject of a number of analyst reports. Cantor Fitzgerald lowered Replimune Group from an "overweight" rating to a "hold" rating in a research report on Monday, April 13th. Leerink Partners reiterated a "market perform" rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Wall Street Zen upgraded shares of Replimune Group from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 23rd. JPMorgan Chase & Co. upgraded shares of Replimune Group from a "neutral" rating to an "overweight" rating and set a $17.00 target price for the company in a report on Friday, June 26th. Finally, Wedbush raised their price target on shares of Replimune Group from $6.00 to $9.00 and gave the company a "neutral" rating in a research report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $8.12.

Replimune Group Trading Down 8.1%

The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The firm has a market cap of $847.79 million, a P/E ratio of -2.98 and a beta of 0.86. The firm's 50-day simple moving average is $8.02 and its 200 day simple moving average is $7.38.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). As a group, analysts expect that Replimune Group, Inc. will post -2.29 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares of the company's stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in shares of Replimune Group during the 4th quarter worth $29,000. Russell Investments Group Ltd. raised its stake in Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC raised its stake in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company's stock valued at $39,000 after acquiring an additional 2,886 shares during the period. Essential Partners LLC lifted its holdings in Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company's stock valued at $43,000 after purchasing an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock valued at $58,000 after purchasing an additional 6,873 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.